The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatitis

Recruiting now

Conditions studied: Atopic Dermatitis

In brief

This study aims to assess the impact of dupilumab on the mental health and quality of life of moderate-to-severe Atopic Dermatitis (AD) patients. The study will recruit participants from AD patients who are already receiving dupilumab treatment. The study enrollment period will be about 9 months with each of the participants undergoing a 6-month observational study period.

Key facts

Study ID

NCT07467564

Run by

Sanofi

People needed

184

Starts

2026-02-24

Expected to finish

2027-05-24

Last updated by the study team

2026-07-28

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants who have moderate to severe AD with signs and symptoms of anxiety and/or depression.
• Participants who initiate dupilumab therapy within 30 days of enrolment, based on the treating physician's decision, independently of study participation
• Participants and/or their legally approved representatives (LAR in case of the minor subject) must agree to sign an informed consent or an assent.

You may not qualify if…

• Females who are pregnant, lactating, or planning/intending to be pregnant in the next 6 months.
• Participants who are participating in another trial.
• Participants with active chronic or acute infection requiring systemic treatment.
• Participants who are diagnosed with active endoparasite infection or are suspected of being at high risk of infection.
• Participants with human immunodeficiency virus (HIV), hepatitis B or C, malignancy, or other concomitant illnesses.
• Participants on antidepressants/anti-anxiety within 6 months of enrolment or those who are planning to receive antidepressants/anti-anxiety. In addition, those who will use antidepressants/anti-anxiety medications throughout the study will be excluded from the analysis.
• The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Where it is running

• Investigational Site: NMC Specialty Hospital LTD — Abu Dhabi, United Arab Emirates (enrolling)
• Investigational Site: Saudi Medical Services (Medical Fakeeh) — Jeddah, Saudi Arabia (enrolling)
• Investigational Site: Dibba Hospital — Fujairah, United Arab Emirates (enrolling)
• Investigational Site: Ibrahem Bin Hamad Hospital — Ras al-Khaimah, United Arab Emirates (enrolling)
• Investigational Site: Al Qassimi Hospital — Sharjah city, United Arab Emirates
• Investigational Site: King Faisal Specialist Hospital — Jeddah, Saudi Arabia
• Investigational Site: Hamad Medical Corporation — Doha, Qatar

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.